Wockhardt Limited (BOM:532300)

Market Cap	227.42B
Revenue (ttm)	30.34B
Net Income (ttm)	-1.23B
Shares Out	n/a
EPS (ttm)	-7.68
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	14,267
Average Volume	42,912
Open	1,415.75
Previous Close	1,394.25
Day's Range	1,393.25 - 1,429.50
52-Week Range	918.85 - 1,870.00
Beta	n/a
RSI	41.82
Earnings Date	Nov 14, 2025

About Wockhardt

Wockhardt Limited, together with its subsidiaries, operates as a pharmaceutical and biotech company, in India, the United States, the United Kingdom, Switzerland, Ireland, Russia, Europe, and internationally. It manufactures and trades pharmaceuticals, medicinal chemical, and botanical products, as well as chemicals and chemical products. The company also develops its flagship antibiotic, ZAYNICH zidebactam/cefepime, a novel beta lactam enhancer mechanism for the treatment of sepsis and hospital/ventilator associated pneumonia; FOVISCU, an anti...

• Industry: Pharmaceutical Preparations
• Founded: 1967
• Employees: 2,296
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 532300

Financial Performance

In 2024, Wockhardt's revenue was 30.35 billion, an increase of 7.24% compared to the previous year's 28.30 billion. Losses were -470.00 million, -89.85% less than in 2023.